## Maria Gisella Cavallo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/780399/publications.pdf

Version: 2024-02-01

103 papers

3,667 citations

32 h-index 56 g-index

104 all docs

104 docs citations

104 times ranked 4910 citing authors

#	Article	IF	CITATIONS
1	The single-point insulin sensitivity estimator (SPISE) index is a strong predictor of abnormal glucose metabolism in overweight/obese children: a long-term follow-up study. Journal of Endocrinological Investigation, 2022, 45, 43-51.	3.3	11
2	High pro-neurotensin levels in individuals with type $1$ diabetes associate with the development of cardiovascular risk factors at follow-up. Acta Diabetologica, 2022, 59, 49-56.	2.5	6
3	Deep Resequencing of 9 Candidate Genes Identifies a Role for ARAP1 and IGF2BP2 in Modulating Insulin Secretion Adjusted for Insulin Resistance in Obese Southern Europeans. International Journal of Molecular Sciences, 2022, 23, 1221.	4.1	4
4	CAPTURE: A cross-sectional study on the prevalence of cardiovascular disease in adults with type 2 diabetes in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1195-1201.	2.6	3
5	Pathogenic variants of MODY-genes in adult patients with early-onset type 2 diabetes. Acta Diabetologica, 2022, , 1.	2.5	1
6	New Insights in the Control of Fat Homeostasis: The Role of Neurotensin. International Journal of Molecular Sciences, 2022, 23, 2209.	4.1	12
7	Contribution of rare variants in monogenic diabetes-genes to early-onset type 2 diabetes. Diabetes and Metabolism, 2022, 48, 101353.	2.9	3
8	Role of Biliverdin Reductase A in the Regulation of Insulin Signaling in Metabolic and Neurodegenerative Diseases: An Update. International Journal of Molecular Sciences, 2022, 23, 5574.	4.1	4
9	Adipose tissue remodelling in obese subjects is a determinant of presence and severity of fatty liver disease. Diabetes/Metabolism Research and Reviews, 2021, 37, e3358.	4.0	27
10	Circulating pro-neurotensin levels predict bodyweight gain and metabolic alterations in children. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 902-910.	2.6	11
11	Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease. Journal of Endocrinological Investigation, 2021, 44, 979-988.	3.3	28
12	Increased PARylation impacts the DNA methylation process in type 2 diabetes mellitus. Clinical Epigenetics, 2021, 13, 114.	4.1	11
13	Biliverdin reductase-A protein levels are reduced in type 2 diabetes and are associated with poor glycometabolic control. Life Sciences, 2021, 284, 119913.	4.3	8
14	Effects of work status changes and perceived stress on glycaemic control in individuals with type 1 diabetes during COVID-19 lockdown in Italy. Diabetes Research and Clinical Practice, 2020, 170, 108513.	2.8	23
15	Granzyme B in Inflammatory Diseases: Apoptosis, Inflammation, Extracellular Matrix Remodeling, Epithelial-to-Mesenchymal Transition and Fibrosis. Frontiers in Immunology, 2020, 11, 587581.	4.8	56
16	Reduced Biliverdin Reductase-A Expression in Visceral Adipose Tissue is Associated with Adipocyte Dysfunction and NAFLD in Human Obesity. International Journal of Molecular Sciences, 2020, 21, 9091.	4.1	13
17	Association of Apelin Levels in Overweight-obese Children with Pubertal Development, but Not with Insulin Sensitivity: 6.5 Years Follow up Evaluation. Endocrine Research, 2020, 45, 233-240.	1.2	5
18	Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update. Nutrients, 2020, 12, 3302.	4.1	85

#	Article	IF	Citations
19	Granzyme B Expression in Visceral Adipose Tissue Associates With Local Inflammation and Glyco-Metabolic Alterations in Obesity. Frontiers in Immunology, 2020, 11, 589188.	4.8	3
20	Relationship between hepatic and systemic angiopoietinâ€like 3, hepatic Vitamin D receptor expression and NAFLD in obesity. Liver International, 2020, 40, 2139-2147.	3.9	25
21	COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications. Diabetes Research and Clinical Practice, 2020, 163, 108165.	2.8	14
22	570-P: Osteoprotegerin Induces Endothelial Dysfunction and Is Associated with Vascular Complications In Type 2 Diabetes. Diabetes, 2020, 69, 570-P.	0.6	1
23	Angiopoietin-Like Protein 4 Overexpression in Visceral Adipose Tissue from Obese Subjects with Impaired Glucose Metabolism and Relationship with Lipoprotein Lipase. International Journal of Molecular Sciences, 2020, 21, 7197.	4.1	19
24	Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus. Journal of Endocrinological Investigation, 2019, 42, 513-520.	3.3	14
25	Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1087-1094.	2.6	19
26	THU-296-Hepatic and visceral adipose tissue expression of vitamin D receptor and vitamin D hydroxylases in relation to non-alcoholic fatty liver disease and adipose tissue inflammation. Journal of Hepatology, 2019, 70, e290.	3.7	0
27	Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation. Journal of Endocrinological Investigation, 2019, 42, 1257-1272.	3.3	58
28	Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity. BMC Medicine, 2019, 17, 85.	5.5	15
29	Reduced biliverdin reductase-A levels are associated with early alterations of insulin signaling in obesity. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1490-1501.	3.8	29
30	ANGPTL4 gene E40K variation protects against obesityâ€associated dyslipidemia in participants with obesity. Obesity Science and Practice, 2019, 5, 83-90.	1.9	13
31	Circulating miRNA-375 levels are increased in autoantibodies-positive first-degree relatives of type $1$ diabetes patients. Acta Diabetologica, 2019, 56, 707-710.	2.5	13
32	Increased circulating granzyme B in type 2 diabetes patients with low-grade systemic inflammation. Cytokine, 2019, 115, 104-108.	3.2	14
33	Technological Support to Intensive Insulin Therapy by a Novel Smartphone Application in Young Adults With Type 1 Diabetes: One Center's Experience. Journal of Diabetes Science and Technology, 2019, 13, 148-149.	2.2	0
34	Overview of studies of the vitamin D/vitamin D receptor system in the development of non-alcoholic fatty liver disease. World Journal of Gastrointestinal Pathophysiology, 2019, 10, 11-16.	1.0	11
35	Procollagenâ€III peptide identifies adipose tissueâ€associated inflammation in type 2 diabetes with or without nonalcoholic liver disease. Diabetes/Metabolism Research and Reviews, 2018, 34, e2998.	4.0	7
36	Presence of diabetes-specific autoimmunity in women with gestational diabetes mellitus (GDM) predicts impaired glucose regulation at follow-up. Journal of Endocrinological Investigation, 2018, 41, 1061-1068.	3.3	13

3

#	Article	IF	Citations
37	Association between systemic leptin and neurotensin concentration in adult individuals with and without type 2 diabetes mellitus. Journal of Endocrinological Investigation, 2018, 41, 1159-1163.	3.3	17
38	Variability in genes regulating vitamin D metabolism is associated with vitamin D levels in type 2 diabetes. Oncotarget, 2018, 9, 34911-34918.	1.8	5
39	Effect of Vitamin D Supplementation on Markers of Vascular Function: A Systematic Review and Individual Participant Metaâ€Analysis. Journal of the American Heart Association, 2018, 7, .	3.7	63
40	Neurotensin Is a Lipid-Induced Gastrointestinal Peptide Associated with Visceral Adipose Tissue Inflammation in Obesity. Nutrients, 2018, 10, 526.	4.1	42
41	Increased Plasma Proneurotensin Levels Identify NAFLD in Adults With and Without Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2253-2260.	3.6	41
42	WISP1 Is a Marker of Systemic and Adipose Tissue Inflammation in Dysmetabolic Subjects With or Without Type 2 Diabetes. Journal of the Endocrine Society, 2017, 1, 660-670.	0.2	45
43	Comment on Elangovan H et al. vitamin D in liver disease: Current evidence and potential directions. Biochim Biophys Acta 2017;1863(4):907–916. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 2388.	3.8	0
44	Circulating IL-8 levels are increased in patients with type 2 diabetes and associated with worse inflammatory and cardiometabolic profile. Acta Diabetologica, 2017, 54, 961-967.	2.5	64
45	High prevalence of diabetesâ€specific autoimmunity in firstâ€degree relatives of Sardinian patients with type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2017, 33, e2864.	4.0	9
46	The Arg282Ser missense mutation in APOA5 gene determines a reduction of triglyceride and LDL-cholesterol in children, together with low serum levels of apolipoprotein A-V. Lipids in Health and Disease, 2017, 16, 179.	3.0	2
47	Vitamin D Supplementation and Non-Alcoholic Fatty Liver Disease: Present and Future. Nutrients, 2017, 9, 1015.	4.1	55
48	Dipeptidyl peptidase-4 inhibitors and bone metabolism: is vitamin D the link?. Acta Diabetologica, 2016, 53, 839-844.	2.5	7
49	Phenotypical heterogeneity linked to adipose tissue dysfunction in patients with TypeÂ2 diabetes. Clinical Science, 2016, 130, 1753-1762.	4.3	16
50	Search for Genetic Variant in the Apelin Gene by Resequencing and Association Study in European Subjects. Genetic Testing and Molecular Biomarkers, 2016, 20, 98-102.	0.7	5
51	No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Medicine, 2016, 14, 92.	5.5	130
52	The vitamin D receptor (VDR) gene rs11568820 variant is associated with type 2 diabetes and impaired insulin secretion in Italian adult subjects, and associates with increased cardio-metabolic risk in children. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 407-413.	2.6	19
53	The "Sapienza University Mortality and Morbidity Event Rate (SUMMER) study in diabetes― Study protocol. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 103-108.	2.6	5
54	Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile. European Journal of Endocrinology, 2016, 174, 187-192.	3.7	24

#	Article	IF	CITATIONS
55	Glycated hemoglobin for the diagnosis of diabetes and prediabetes: Diagnostic impact on obese and lean subjects, and phenotypic characterization. Journal of Diabetes Investigation, 2015, 6, 44-50.	2.4	33
56	Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control. Acta Diabetologica, 2015, 52, 873-880.	2.5	19
57	Hypovitaminosis D in recent onset rheumatoid arthritis is predictive of reduced response to treatment and increased disease activity: a 12Âmonth follow-up study. BMC Musculoskeletal Disorders, 2015, 16, 53.	1.9	40
58	TSH levels are associated with vitamin D status and seasonality in an adult population of euthyroid adults. Clinical and Experimental Medicine, 2015, 15, 389-396.	3.6	41
59	Hypovitaminosis D is Independently Associated with Metabolic Syndrome in Obese Patients. PLoS ONE, 2013, 8, e68689.	2.5	49
60	Association of <i>FTO </i> Polymorphisms with Early Age of Obesity in Obese Italian Subjects. Experimental Diabetes Research, 2012, 2012, 1-7.	3.8	36
61	Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology, 2012, 56, 2180-2187.	7.3	192
62	Altered Glucose Homeostasis Is Associated with Increased Serum Apelin Levels in Type 2 Diabetes Mellitus. PLoS ONE, 2012, 7, e51236.	2.5	47
63	Metabolic syndrome in subjects at high risk for type 2 diabetes: The genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 699-705.	2.6	16
64	High prevalence of capillary abnormalities in patients with diabetes and association with retinopathy. Diabetic Medicine, 2011, 28, 1039-1044.	2.3	49
65	Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Medicine, 2011, 9, 85.	5.5	257
66	Blue eyes as a risk factor for type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2011, 27, 609-613.	4.0	16
67	Prevalence of Type 1 Diabetes Autoantibodies (GADA, IA2, and IAA) in Overweight and Obese Children. Diabetes Care, 2010, 33, 820-822.	8.6	21
68	No Protective Effect of Calcitriol on $\hat{l}^2$ -Cell Function in Recent-Onset Type 1 Diabetes. Diabetes Care, 2010, 33, 1962-1963.	8.6	133
69	Subclinical vascular alterations in young adults with type $1$ diabetes detected by arterial tonometry. Diabetes/Metabolism Research and Reviews, 2009, 25, 756-761.	4.0	6
70	Insulinoma CM cell line as in vitro model for betaâ€cell. Journal of Cellular Physiology, 2008, 216, 568-568.	4.1	3
71	Search for genetic variants of the SYNTAXIN 1A (STX1A) gene: the â^'352 A>T variant in the STX1A promoter associates with impaired glucose metabolism in an Italian obese population. International Journal of Obesity, 2008, 32, 413-420.	3.4	27
72	Cytokines in sera from insulin-dependent diabetic patients at diagnosis. Clinical and Experimental Immunology, 2008, 86, 256-259.	2.6	63

#	Article	IF	Citations
73	Cytokines and autoimmunity. Clinical and Experimental Immunology, 2008, 96, 1-7.	2.6	38
74	Identification of Sequence Variants in the UBL5 (Ubiquitin-like 5 or BEACON) Gene in Obese Children by PCR-SSCP: No Evidence for Association with Obesity. Journal of Pediatric Endocrinology and Metabolism, 2008, 21, 1139-45.	0.9	3
75	Age at Diagnosis of Type 1 Diabetes and the Effect of Immunomodulatory Therapies on Residual Beta Cell Function. Hormone and Metabolic Research, 2008, 40, 66-68.	1.5	1
76	The effects of calcitriol and nicotinamide on residual pancreatic βâ€cell function in patients with recentâ€onset TypeÂ1 diabetes (IMDIABÂXI). Diabetic Medicine, 2006, 23, 920-923.	2.3	116
77	3,5,3′-triiodothyronine (T3) is a survival factor for pancreatic β-cells undergoing apoptosis. Journal of Cellular Physiology, 2006, 206, 309-321.	4.1	69
78	The G972R variant of the insulin receptor substrate-1 gene impairs insulin signaling and cell differentiation in 3T3L1 adipocytes; treatment with a PPAR $\hat{I}^3$ agonist restores normal cell signaling and differentiation. Journal of Endocrinology, 2006, 188, 271-285.	2.6	19
79	Clinical phenotype and $\hat{l}^2$ -cell autoimmunity in Italian patients with adult-onset diabetes. European Journal of Endocrinology, 2006, 154, 441-447.	3.7	46
80	Insulin Resistance, the Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1578-1582.	3.6	252
81	Tumor necrosis factor alpha (TNFα) and its soluble receptor p75 (sTNF-R p75) in familial combined hyperlipidemia (FCHL). Nutrition, Metabolism and Cardiovascular Diseases, 2005, 15, 262-269.	2.6	3
82	Biokinetics of buccal spray insulin in patients with type 1 diabetes. Metabolism: Clinical and Experimental, 2005, 54, 930-934.	3.4	28
83	Cytokine profile and insulin antibody IgG subclasses in patients with recent onset Type 1 diabetes treated with oral insulin. Diabetologia, 2004, 47, 1795-1802.	6.3	24
84	Establishment of T cell lines to bovine beta-casein and beta-casein-derived epitopes in patients with type 1 diabetes. Journal of Endocrinology, 2003, 176, 143-150.	2.6	17
85	Antibodies to Bovine Beta-Casein in Diabetes and Other Autoimmune Diseases. Hormone and Metabolic Research, 2002, 34, 455-459.	1.5	27
86	Continuous glucose monitoring during the European Soccer cup semifinal, Italy against Holland. Diabetologia, 2001, 44, 268-268.	6.3	3
87	Intradermal skin test with diabetes specific antigens in patients with type 1 diabetes. Clinical and Experimental Immunology, 2001, 123, 382-386.	2.6	1
88	No effect of oral insulin on residual beta-cell function in recent-onset Type I diabetes (the IMDIAB VII). Diabetologia, 2000, 43, 1000-1004.	6.3	207
89	Natural Resistance of Human Beta Cells toward Nitric Oxide Is Mediated by Heat Shock Protein 70. Journal of Biological Chemistry, 2000, 275, 19521-19528.	3.4	74
90	Beta-cell gene expression and functional characterisation of the human insulinoma cell line CM. Journal of Endocrinology, 1999, 161, 59-68.	2.6	58

#	Article	lF	CITATIONS
91	T Cell Reactivity to Human Insulinoma Cell Line (CM) Antigens in Patients with Type 1 Diabetes. Autoimmunity, 1999, 29, 171-177.	2.6	7
92	High frequency of polymorphism but no mutations found in the GLUT1 glucose transporter gene in NIDDM and familial obesity by SSCP analysis. Human Genetics, 1998, 102, 479-482.	3.8	7
93	Metabolic and immune parameters at clinical onset of insulin-dependent diabetes: A population-based study. Metabolism: Clinical and Experimental, 1998, 47, 1205-1210.	3.4	61
94	Sex Steroids Do Not Prevent Amylin-Induced Apoptosis in Human Cells. Experimental Cell Research, 1998, 241, 265-268.	2.6	6
95	Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study). European Journal of Endocrinology, 1997, 137, 234-239.	3.7	49
96	Cell-mediated immune response to $\hat{l}^2$ casein in recent-onset insulin-dependent diabetes: implications for disease pathogenesis. Lancet, The, 1996, 348, 926-928.	13.7	143
97	Beta-cell markers and autoantigen expression by a human insulinoma cell line: similarities to native beta cells. Journal of Endocrinology, 1996, 150, 113-120.	2.6	21
98	Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia, 1995, 38, 848-852.	6.3	68
99	Combination of Nicotinamide and Steroid Versus Nicotinamide in Recent-Onset IDDM: The IMDIAB II Study. Diabetes Care, 1994, 17, 897-900.	8.6	14
100	Affected sib-pair analysis of the GLUT1 glucose transporter gene locus in non-insulin-dependent diabetes mellitus (NIDDM): evidence for no linkage. Human Genetics, 1994, 93, 675-80.	3.8	8
101	Randomized Trial Comparing Nicotinamide and Nicotinamide Plus Cyclosporin in Recent Onset Insulinâ€dependent Diabetes (IMDIAB 1). Diabetic Medicine, 1994, 11, 98-104.	2.3	34
102	Polymorphisms at the GLUT2 (βâ€cell/liver) glucose transporter gene and nonâ€nsulinâ€dependent diabetes mellitus (NIDDM): analysis in affected pedigree members. Clinical Genetics, 1992, 41, 229-234.	2.0	17
103	The immune response to influenza vaccination in diabetic patients. Diabetologia, 1986, 29, 850-854.	6.3	70